echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Neurology: Ubrogepant in the treatment of mild pain in the acute phase of migraine versus moderate pain in severe pain

    Neurology: Ubrogepant in the treatment of mild pain in the acute phase of migraine versus moderate pain in severe pain

    • Last Update: 2022-09-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    During migraine attacks, mild pain at the time of the attack tends to escalate to moderate or severe pain
    .


    Phase III, open-label, dose-blinded 52-week extended trial
    .


    Compared with episodes treated with moderate or severe pain, the use of ubroepant during mild pain leads to a significantly higher pain-free rate, no associated symptoms, and normal function
    is achieved two hours after administration.


    This study provides class III evidence that ubroepant, 50 mg or 100 mg used by adults with mild migraine, increases the likelihood
    of being free from migraine headache pain, migraine-related symptoms, and disability after 2 hours compared with moderate to severe migraine.


    Source: Lipton RB, Dodick D, Goadsby PJ, et al.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.